《WHO基本药物示范目录》中抗肿瘤药物的变化及对我国《国家基本药物目录》修订的启示  

Analysis on changes in anti-tumor drug in WHO essential model list and the effect on revision of national essential medicines list

作　　者：闫加庆 刘敏 马颖林 乐凯迪 董斌 李国辉 YAN Jia-qing;LIU Min;MA Ying-lin;LE Kai-di;DONG Bin;LI Guo-hui(Department of Pharmacy,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院药剂科,北京100021

出　　处：《临床药物治疗杂志》2021年第4期54-57,共4页Clinical Medication Journal

摘　　要：目的比较2018版《国家基本药物目录》(NEML-2018)与2019版《WHO基本药物示范目录》(WHO-EML-2019)中抗肿瘤药物目录的差别,为NEML的持续完善提供参考。方法采用描述性分析方法,从药品种类、数目、剂型、规格、适应证及儿童用药等方面对我国NEML-2018和WHO-EML-2019中收录的肿瘤药物进行比较,并对存在的问题进行分析。结果 NEML-2018中抗肿瘤药物的遴选基本符合我国国情和肿瘤流行病学特点,其与WHO-EML-2019收录的抗肿瘤药物品种数分别为35和59种,注射剂型分别为26和40种,口服剂型分别为15和30种。此外,NEML-2018没有专门的适应证描述和儿童用药标识。结论与WHO-EML-2019相比,NEML-2018收录的抗肿瘤药物在药品种类、数量、剂型、规格、适应证和儿童用药标识方面均存在差距,今后NEML的修订要以WHO-EML为参考,加强循证评价和药物经济学分析,不断优化抗肿瘤药物目录的遴选。Objective The differences of anti-cancer drug list between national essential medicines list 2018(NEML-2018)and WHO essential model list 2019(WHO-EML-2019)were compared in order to provide reference for the improvement of NEML in the future. Methods The differences in category,content,formulation,dosage forms,special identification for children as well as indications for use were compared between the two lists,and the existing problems were also analyzed.Results The anti-cancer drug list in NEML-2018 was basically consistent with the epidemic characteristics of cancer in China. Compared with WHO-EML-2019,the number of anti-cancer drugs included in the two lists was 35 and 59;the dosage form for injection and oral was 26-40 and 15-30 respectively. Otherwise,special indications for clinical use and identification for children were lacked in NEML-2018. Conclusion Compared with WHO-EML-2019,some disadvantages were still existing in NEML-2018 including category,content,formulation,dosage forms and special indications. Taking WHO-EML as reference,evidence-based evaluation and pharmacoeconomic analysis should be considered in the future revision of anti-cancer drug list in NEML.

关 键 词：国家基本药物目录 世界卫生组织基本药物示范目录 抗肿瘤药物目录 

分 类 号：R95[医药卫生—药学]